Thermo Fisher Scientific (TMO) Other Non-Current Liabilities (2009 - 2026)

Thermo Fisher Scientific (TMO) has reported Other Non-Current Liabilities for 18 consecutive years, with $4.5 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Non-Current Liabilities rose 6.28% year-over-year to $4.5 billion; the trailing twelve-month figure through Jun 2026 stood at $4.5 billion (up 6.28% YoY), and the FY2025 full-year result was $4.3 billion, up 7.12% from the prior year.
• Other Non-Current Liabilities climbed to $4.5 billion in Q2 2026 per TMO's latest filing, from $4.4 billion in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $4.7 billion in Q2 2022 and bottomed at $4.0 billion in Q1 2025.
• Historically, Other Non-Current Liabilities has averaged $4.3 billion across 5 years, with a median of $4.3 billion in 2023.
• The sharpest annual moves came in 2022 and 2024: Other Non-Current Liabilities soared 39.14% in 2022, then retreated 14.07% in 2024.
• Over 5 years, Other Non-Current Liabilities stood at $4.2 billion in 2022, then increased by 9.53% to $4.6 billion in 2023, then dropped by 14.07% to $4.0 billion in 2024, then gained by 7.12% to $4.3 billion in 2025, then grew by 6.2% to $4.5 billion in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $4.5 billion, $4.4 billion, and $4.3 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.